Wilson Sonsini Goodrich & Rosati
VC Fund
Palo Alto, United States
Wilson Sonsini Goodrich & Rosati is a VC fund in Palo Alto focused on Software and Biotechnology. Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. They represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks thatfinance and advise them. The firm's broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of their clients.The firm is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Their services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law, among other areas. Their distinguished international roster of clients span a wide variety of industries, including information technology, life sciences, energy and clean technology, media and entertainment, communications, retail, and financial services.
- Total investments:
- 117
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries Wilson Sonsini Goodrich & Rosati invests in
Stages Wilson Sonsini Goodrich & Rosati invests in
Countries Wilson Sonsini Goodrich & Rosati invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 18 contacts → | |||
Round size
- Seed
- $450k–$7.3M
- Series A
- $3M–$15M
- Series B
- $8.5M–$55M
Investment Focus
Industry
- Software 23 (20%)
- Biotechnology 17 (15%)
- Health Care 14 (12%)
- Artificial Intelligence 14 (12%)
- Information Technology 12 (10%)
Stage
- Seed 39 (33%)
- Series A 32 (27%)
- Series B 15 (13%)
- Funding Round 7 (6%)
- Pre-Seed 6 (5%)
Country
- United States 97 (83%)
- Kenya 1 (1%)
- Israel 1 (1%)
- Hong Kong 1 (1%)
- El Salvador 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Martin Waters
Partner
|
Partner | Total investments: 1 | Find email | |
David Wanek
Law Clerk
|
Law Clerk | Total investments: 1 | Find email | |
Donald E. Bradley
General Counsel
|
General Counsel | Total investments: 0 | Find email | |
Douglas J. Clark
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Jeffrey Saper
Vice Chairman
|
Vice Chairman | Total investments: 0 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Latitude
|
Latitude is working on a global payments system that links stablecoin-based settlement with local currency payout systems. | $35M / Series A / Sep 08, 2026 | |
NANOCHON
|
Nanochon is a biotech and medical device company specializing in the development of innovative orthopedic solutions. The company develops medical implant technology focused on cartilage repair for patients with joint surface damage. Its primary product, Chondrograft, is a 3D-printed, synthetic implant engineered to replace lost or damaged cartilageand support the body’s own tissue repair. The design uses a nylon-based composite with structural properties intended to mimic natural cartilage and fit securely into defects using a press-fit surgical procedure. Nanochon’s solution targets individuals who require more than temporary relief but are not yet candidates for total joint replacement, offering an off-the-shelf device that integrates with the healing process. The company’s work includes advancing clinical evaluation and surgical use of its implant technology. | $4.1M / Seed / Jan 12, 2026 | |
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals develops and investigates targeted small molecule therapeutics aimed at restoring cellular metabolic quality control to address dysregulated growth and signaling linked to certain rare genetic and age-related conditions. The company’s pipeline centers on compounds that selectively modulate specific biological pathways,including inhibitors designed to influence disease processes associated with neurological dysfunction. Its lead development candidate is a central nervous system-penetrant selective inhibitor being evaluated in clinical trials for refractory seizures related to a genetic disorder, and additional compounds are in earlier stages of investigation for other disease areas. Aeovian Pharmaceuticals also maintains a portfolio of proprietary molecules that engage defined molecular targets to explore potential treatments beyond its program. | $55M / Series B / Dec 16, 2025 | |
Sober Sidekick
|
Gamified peer to peer support | $7.6M / Venture - Series Unknown / Dec 03, 2025 | |
Iambic
|
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M / Nov 10, 2025 | |
Coral Vita
|
Coral Vita grows corals to revitalize dying reefs. | $8M / Series A / Jun 06, 2025 | |
Neon Mobile
|
Neon Mobile is an online application that offers to pay customers for their anonymized phone call data. | $1.5M / Pre-Seed / May 27, 2025 | |
SingleFile Technologies
|
SingleFile is an AI-powered compliance platform automating compliance filings and annual reports across 50 states for complex multi-entity organizations. The platform centralizes Secretary of State filings, annual reports, EIN applications, and service-of-process management in a single collaborative workspace designed for organizations managinglarge entity portfolios at scale.SingleFile's technology automates jurisdiction-specific requirements across all 50 states and the District of Columbia, processing thousands of filings in minutes rather than days. Services include entity formations, foreign qualifications, certificates of good standing, amendments, apostilles, and certified document retrieval.The multi-user platform enables seamless collaboration between organizations and their outside counsel or fund administrators, with audit-ready documentation and a pricing model that charges only for services performed—no per-user or per-entity fees. | $9.1M / Series A / Feb 19, 2025 | |
General Proximity
|
General Proximity is a pioneering future-oriented proximity medicine that envisions the future of medicine. | $16M / Seed / Jan 03, 2025 | |
nChroma Bio
|
nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques. | $75M / Venture - Series Unknown / Dec 11, 2024 | |
| See all 117 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Wilson Sonsini Goodrich & Rosati invest in?
Wilson Sonsini Goodrich & Rosati invests primarily in Software, Biotechnology and Health Care startups, most often at Seed and Series A stage. Most of the 117 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Wilson Sonsini Goodrich & Rosati's check size?
Wilson Sonsini Goodrich & Rosati typically joins rounds of $450k–$7.3M at Seed, $3M–$15M at Series A and $8.5M–$55M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wilson Sonsini Goodrich & Rosati participates in.
How do I contact Wilson Sonsini Goodrich & Rosati?
Public channels for Wilson Sonsini Goodrich & Rosati include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wilson Sonsini Goodrich & Rosati?
The team at Wilson Sonsini Goodrich & Rosati includes Martin Waters (Partner), David Wanek (Law Clerk) and Donald E. Bradley (General Counsel), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
